Dapagliflozin is a sodium-glucose cotransporter 2 inhibitor indicated for managing diabetes mellitus type 2. When combined with diet and exercise in adults, dapagliflozin helps to improve glycemic control by inhibiting glucose resorption in the proximal tubule of the nephron and causing glycosuria. Dapagliflozin was approved by the FDA on Jan 08, 2014.
Metformin is a biguanide drug used in conjunction with diet and exercise for glycemic control in type 2 diabetes mellitus and used off-label for insulin resistance in polycystic ovary syndrome (PCOS).
Dapagliflozin 5/10mg Tablets, Dapagliflozin 5/10mg + Metformin 500mg SR Tablets, Dapagliflozin 5/10mg + Metformin 1000mg SR Tablets.
MODE OF ACTION:
Dapagliflozin inhibits the sodium-glucose contransporter 2 (SGLT2) which is primarily located in the proximal tubule of the nephron. SGLT2 facilitates 90% of glucose resorption in the kidneys and so its inhibition allows for glucose to be excreted in the urine. This excretion allows for better glycemic control and potentially weight loss in patients with type 2 diabetes mellitus. Metformin decreases blood glucose levels by decreasing hepatic glucose production (gluconeogenesis), decreasing the intestinal absorption of glucose, and increasing insulin sensitivity by increasing peripheral glucose uptake and utilization.
- To improve glycemic control in T2DM.
As per doctor’s direction
This information is for registered medical practitioner only. Anyone other than medical practitioner should consult medical practitioner before using this product.